The potential of PSMA as a molecular target for PCa was first established through immunoscintigraphy studies using the mAb 7E11 radiolabeled with indium-111, commercially known as ProstaScint® and approved by the FDA in the late 1990s [82]. This evidence concerns the gene FOLH1 and posterior cortical atrophy.